# Amivantamab plus lazertinib vs osimertinib in first-line <i>EGFR</i>-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/amivantamab-plus-lazertinib-vs-osimertinib-in-first-line-i-egfr-i-mutant/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Enriqueta Felip,Byoung Chul Cho,Vanesa Gutiérrez,Adlinda Alip,Benjamin Besse,Shun Lu,Alexander I. Spira,Nicolas Girard,Raffaele Califano,Shirish M. Gadgeel,James Chih‐Hsin Yang,Naoyuki Nogami,Koichi Azuma,Joshua C. Curtin,Jiarui Zhang,Anesh Panchal,Mariah Ennis,Seema Sethi,Joshua Bauml,Se‐Hoon Lee |
| Citations | 17 |
| DOI | 10.1200/jco.2024.42.16_suppl.8504 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4400036602 |
| Type | conference-abstract |
| Year | 2024 |

## Paper authors

- [Adlinda Alip](https://scholariq.org/researchers/adlinda-alip/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Paper topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.